Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (SHE:301096)

SHE:301096 Revenue

Hangzhou Bio-Sincerity Pharma-Tech had revenue of 143.98M CNY in the quarter ending June 30, 2026, a decrease of -29.29%. This brings the company's total for the last twelve months to 650.08M, up 6.71% year-over-year. In the year 2025, Hangzhou Bio-Sincerity Pharma-Tech had annual revenue of 677.99M, down -15.45%. That makes Hangzhou Bio-Sincerity Pharma-Tech the 22,854th largest company in the world by revenue and 4,166th in China.

• Revenue (ttm): 650.08M
• Revenue Growth: +6.71%
• P/S Ratio: 7.12
• Revenue / Employee: 460.39K
• Employees: 1,412
• Market Cap: 4.63B

Revenue Chart

Chart

Chart

Revenue by Geography

Chart

• China 677.54M 99.9%
• Overseas 446.33K 0.1%

Fiscal year ended Dec 31, 2025 See the full SHE:301096 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	677.99M	-123.94M	-15.45%
Dec 31, 2024	801.92M	-215.52M	-21.18%
Dec 31, 2023	1.02B	410.04M	67.51%
Jan 1, 2023	607.41M	233.10M	62.27%
Dec 31, 2021	374.31M	167.06M	80.61%

Data Source: S&P Global Market Intelligence Last updated: Aug 26, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 28, 2026

Data Sources Report a data error